| Site-specific DICER and DROSHA RNA products control the DNA-damage response S Francia, F Michelini, A Saxena, D Tang, M De Hoon, V Anelli, M Mione, ... Nature 488 (7410), 231-235, 2012 | 616 | 2012 |
| Damage-induced lncRNAs control the DNA damage response through interaction with DDRNAs at individual double-strand breaks F Michelini, S Pitchiaya, V Vitelli, S Sharma, U Gioia, F Pessina, M Cabrini, ... Nature Cell Biology, 2017 | 377 | 2017 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 238 | 2020 |
| A damaged genome’s transcriptional landscape through multilayered expression profiling around in situ-mapped DNA double-strand breaks F Iannelli, A Galbiati, I Capozzo, Q Nguyen, B Magnuson, F Michelini, ... Nature communications 8 (1), 15656, 2017 | 119 | 2017 |
| Bystander effect of antibody–drug conjugates: fact or fiction? F Giugliano, C Corti, P Tarantino, F Michelini, G Curigliano Current oncology reports 24 (7), 809-817, 2022 | 89 | 2022 |
| From “cellular” RNA to “smart” RNA: multiple roles of RNA in genome stability and beyond F Michelini, AP Jalihal, S Francia, C Meers, ZT Neeb, F Rossiello, U Gioia, ... Chemical reviews 118 (8), 4365-4403, 2018 | 89 | 2018 |
| Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs U Gioia, S Francia, M Cabrini, S Brambillasca, F Michelini, ... Scientific reports 9 (1), 6460, 2019 | 75 | 2019 |
| MRE11-RAD50-NBS1 Complex Is Sufficient to Promote Transcription by RNA Polymerase II at Double-Strand Breaks by Melting DNA Ends S Sharma, R Anand, X Zhang, S Francia, F Michelini, A Galbiati, ... Cell Reports 34 (1), 108565, 2021 | 62 | 2021 |
| Prolonged lifespan with enhanced exploratory behavior in mice overexpressing the oxidized nucleoside triphosphatase hMTH1 G De Luca, I Ventura, V Sanghez, MT Russo, MA Ajmone‐Cat, E Cacci, ... Aging cell 12 (4), 695-705, 2013 | 47 | 2013 |
| Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors Y Cai, G Xu, F Wu, F Michelini, C Chan, X Qu, P Selenica, E Ladewig, ... Cancer research 81 (9), 2470-2480, 2021 | 27 | 2021 |
| 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the … BT Li, F Meric-Bernstam, A Bardia, Y Naito, S Siena, PG Aftimos, ... Annals of Oncology 34, S459-S460, 2023 | 20 | 2023 |
| Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study BT Li, F Meric-Bernstam, A Bardia, Y Naito, S Siena, P Aftimos, I Anderson, ... The lancet oncology 25 (6), 707-719, 2024 | 19 | 2024 |
| RNase A treatment and reconstitution with DNA damage response RNA in living cells as a tool to study the role of non-coding RNA in the formation of DNA damage response foci F Michelini, F Rossiello, FA di Fagagna, S Francia Nature Protocols, 1, 2019 | 11 | 2019 |
| Cytogenetic analysis of human cells reveals specific patterns of DNA damage in replicative and oncogene‐induced senescence G Falcone, A Mazzola, F Michelini, G Bossi, F Censi, MG Biferi, ... Aging Cell 12 (2), 312-315, 2013 | 10 | 2013 |
| Complete remission of widely metastatic human epidermal growth factor receptor 2–amplified pancreatic adenocarcinoma after precision immune and targeted therapy with … DA King, AR Smith, G Pineda, M Nakano, F Michelini, SP Goedegebuure, ... JCO Precision Oncology 7, e2100489, 2023 | 7 | 2023 |
| The oncogenic PI3K-induced transcriptomic landscape reveals key functions in splicing and gene expression regulation E Ladewig, F Michelini, K Jhaveri, P Castel, J Carmona, L Fairchild, ... Cancer research 82 (12), 2269-2280, 2022 | 7 | 2022 |
| HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov, 2020, 10 (5): 674-687. doi: 10.1158/2159-8290 BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai CD-20-0215, 0 | 7 | |
| Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. PJ Wysocki, KH Jung, DY Oh, DB Doroshow, E Artamonova, L Mammatas, ... Journal of Clinical Oncology 42 (16_suppl), 4565-4565, 2024 | 4 | 2024 |
| Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). DY Oh, IA Lugowska, D Stroyakovskiy, KH Jung, O Dumas, K Penkov, ... Journal of Clinical Oncology 42 (16_suppl), 4090-4090, 2024 | 4 | 2024 |
| Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling DA King, AR Smith, G Pineda, M Nakano, F Michelini, SP Goedegebuure, ... medRxiv, 2021.12. 16.21267326, 2021 | 2 | 2021 |
Sofia FranciaResercher at Istituto di Genetica Molecolare-Consiglio Nazionale delle RicercheAdresă de e-mail confirmată pe igm.cnr.it
